EcoDrugPlus

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSDNOG00000042747
Gene Symbol: PSMB3
2 Cross references
258 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSDNOG00000018255
Gene Symbol: PSMB4
4 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSDNOG00000045865
Gene Symbol: PSMB5
2 Cross references
223 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSDNOG00000015332
Gene Symbol: PSMB7
2 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSDNOG00000045248
Gene Symbol: PSMB8
2 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSDNOG00000035353
Gene Symbol: PSMB9
4 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSDNOG00000002073
Gene Symbol: PSMD2
4 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSDNOG00000002708
Gene Symbol: PSMC2
2 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSDNOG00000033470
Gene Symbol: PSMC3
4 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSDNOG00000031323
Gene Symbol: PSMC4
4 Cross references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSDNOG00000002393
Gene Symbol: PSMC5
3 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSDNOG00000002660
Gene Symbol: PSMC6
4 Cross references
197 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).